

June 7, 2021

# Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

NEW YORK, June 7, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, is scheduled to participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 8:00 a.m. Eastern Time.



Participants may access a live webcast of the event through the following link:

<https://kvgo.com/gs-global-healthcare/relmada-therapeutics-inc-june-2021>

The webcast can also be accessed in the Investors section of the Relmada website at <https://www.relmada.com/investors/ir-calendar>. An archived replay of the event will be available for one year after the conclusion of the presentation.

## About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. Learn more at [www.relmada.com](http://www.relmada.com).

## Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results

to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

**Investor Contact:**

Tim McCarthy  
LifeSci Advisors  
212-915-2564  
[Tim@LifeSciAdvisors.com](mailto:Tim@LifeSciAdvisors.com)

**Media Inquiries:**

FischTank PR  
[Relmada@FischTankPR.com](mailto:Relmada@FischTankPR.com)

 View original content to download multimedia <http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-participation-in-goldman-sachs-42nd-annual-global-healthcare-conference-301306512.html>

SOURCE Relmada Therapeutics, Inc.